CAR-T cell therapy

"More than 70% of patients with refractory or relapsed leukemia and lymphoma respond to CAR-T cell treatment".


What is CAR-T cell therapy?

CAR-T cell therapy is a novel cellular immunotherapy procedure indicated for some hematological tumors.

The clinical application of this technique, which combines cell therapy and gene therapy, has been shown to be particularly effective in patients with certain types of leukemias, lymphomas and myelomas.

The Advanced Therapies Unit of the Clínica Universidad de Navarra has internationally renowned professionals with experience in the diagnosis and treatment of hematological cancers. A trajectory that has made it possible to advance in the administration of CAR-T cell treatment for our patients.

The research carried out in collaboration with the Cima Universidad de Navarra drives the search for new clinical indications and seeks to increase the efficacy and safety of these treatments.

Imagen del icono de la consulta de Segunda Opinión. Clínica Universidad de Navarra

Do you need our help?
Contact with us

Why choose the Clínica Universidad de Navarra?

We are the best private hospital in Spain for the seventh time in a row
(Health Reputation Monitor Ranking 2020)

Imagen de un icono dorado de un sello que acredita la excelencia en la atención.


More than 25 years of research and transplantation of haematopoietic progenitors and other advanced therapies.

Imagen de un icono dorado de un equipo de tres personas.

Multidisciplinary team

Professionals from different specialities and an advanced nursing team with a long history of experience in dealing with these treatments.

Imagen de un icono dorado que representa el cuidado de la salud.

Comprehensive approach

Highly experienced nurses in the care of patients with hematological disease, who have undergone bone marrow transplant and CAR-T cell treatment.

How does CAR-T cell treatment work?

T cells are cells of the immune system that are formed from stem cells in the bone marrow. They are also called T-lymphocytes and their main function is to participate in protecting the body against infections, but they can also fight against cancer cells.

CAR-T cell therapy or chimeric antigen receptor T-cell therapy (CART) involves genetically modifying these immune cells to give them the tools to recognize and destroy tumor cells more effectively.

Most frequent indications for CAR-T cell therapy

Do you have any of these diseases?

May be a candidate for CAR-T cell therapy

What is the CAR-T cell treatment process like?

Re-evaluation of the disease

If the patient is a possible candidate, the Hematology Service of the Clínica Universidad de Navarra performs the necessary tests within 24-48 hours to confirm that the patient is suitable for this treatment.

Obtaining T lymphocytes

Approximately one week after the results are known, apheresis of the patient's blood is performed at the Clinica's Day Hospital to obtain the T lymphocytes to be modified.

Preparation of CAR-T cells

The cells obtained are sent to the laboratory where they are genetically engineered. The process usually takes between 4-5 weeks.

Millions of CAR-T cells are produced to fight cancer.

Bridge therapy

While the laboratory prepares the product, the patient will receive 1-2 cycles of chemotherapy, depending on the status of the disease.

Lymphodepletion therapy

4 or 5 days before the infusion of CAR-T cells, the patient undergoes chemotherapy treatment to prepare the body to receive the treatment.

CAR-T cell infusion

The patient is admitted to the Clinic and the CAR-T cells are infused. The patient will remain between 14-21 days for monitoring and treatment of complications, should they appear.

Where do we do it?


The Hematology and Hemotherapy Service of the
at the Clínica Universidad de Navarra

The Hematology Service of the Clinic, formed by specialists of recognized national and international prestige, has integrated molecular diagnostic techniques and the use of new personalized treatments in its assistance work, allowing a more precise and fast diagnosis of the hematological diseases.

The joint work of the medical staff and the researcher facilitates the development and application of the new treatments and at the same time the precise evaluation of the result of the treatments.

Imagen de la fachada de consultas de la sede en Pamplona de la Clínica Universidad de Navarra

Why at the Clinica?

  • Experts in the development of Cellular Therapy treatments.
  • International reference center in lymphomas, multiple myeloma and monoclonal gammopathies.
  • Experts in the diagnosis and treatment of hemorrhagic and thrombotic problems.

Our team of professionals

Hematology specialists with experience in CART cell therapy